

**COLON  
DISEASE ORIENTED GROUP  
AGENDA**

**OPEN SESSION**

VENUE: ROSSETTI ROOM, EATON CHELSEA HOTEL, TORONTO

DATE SATURDAY, MAY 3<sup>rd</sup>, 2014

TIME: 8:00 – 10:00

**CHAIRS: DR. DEREK JONKER, DR. SHARLENE GILL**

---

- |             |   |                                    |
|-------------|---|------------------------------------|
| 8:00        | WELCOME AND INTRODUCTION  | <b>DR. D. JONKER / DR. S. GILL</b> |
| 8:05 – 8:35 | APPROVED/ACTIVE TRIALS FOR DISCUSSION   |                                    |
|             | <b>IND 208:</b> A PHASE I TRIAL OF PANITUMUMAB + BKM120, AN ORAL PI3K INHIBITOR, IN COLORECTAL CANCER   | <b>DR. R. GOODWIN</b>              |
|             | <b>IND 210:</b> A RANDOMIZED PHASE II STUDY OF FOLFOX/BEVACIZUMAB +/- REOLYSIN IN METASTATIC COLORECTAL CANCER  | <b>DR. P. TANG</b>                 |
|             | <b>IND 214:</b> A PHASE I/II TRIAL OF MG1MA3 WITH AND WITHOUT ADVAC/MA3 IN PATIENTS WITH ADVANCED/METASTATIC COLORECTAL OR NON SMALL CELL LUNG CANCER                           | <b>DR. D. JONKER</b>               |
|             | <b>CRC.6:</b> (CALGB 80702): A PHASE III TRIAL OF 6 VERSUS 12 TREATMENTS OF ADJUVANT FOLFOX PLUS CELECOXIB OR PLACEBO FOR PATIENTS WITH RESECTED STAGE III COLON CANCER         | <b>DR. F. COUTURE</b>              |
|             | <b>CO.23:</b> A PHASE III RANDOMIZED STUDY OF BBI608 AND BEST SUPPORTIVE CARE VERSUS PLACEBO AND BEST SUPPORTIVE CARE IN PATIENTS WITH PRETREATED ADVANCED COLORECTAL CARCINOMA | <b>DR. D. JONKER</b>               |
| 8:35 – 9:25 | CONCEPTS IN DEVELOPMENT/TRIAL PROPOSALS   |                                    |
|             | <b>SWOG 1406:</b> RANDOMIZED PHASE II STUDY IN BRAF MUTANT MCRC (IRINOTECAN/CETUXIMAB VS VEMURAFENIB/CETUXIMAB VS VEMURAFENIB/IRINOTECAN/CETUXIMAB)                             | <b>DR. H. KENNECKE</b>             |
|             | <b>ASSIGN</b> INTERGROUP TRIAL  | <b>DR. D. JONKER</b>               |
|             | <b>AsPIK STUDY:</b> ASPIRIN FOR PIK3CA MUTATED DUKES C AND HIGH RISK DUKES B COLORECTAL CANCERS – A MULTI-CENTRE, DOUBLE BLIND, RANDOMIZED, PLACEBO CONTROLLED, PHASE III TRIAL | <b>DR. S. GILL</b>                 |

COLON  
DISEASE ORIENTED GROUP  
AGENDA

**OPEN SESSION**

VENUE: ROSSETTI ROOM, EATON CHELSEA HOTEL, TORONTO

DATE SATURDAY, MAY 3<sup>rd</sup>, 2014

TIME: 8:00 – 10:00

**CHAIRS: DR. DEREK JONKER, DR. SHARLENE GILL**

---

CONCEPTS IN DEVELOPMENT/TRIAL PROPOSALS (continued)

PERIOPERATIVE LOW MOLECULAR WEIGHT HEPARIN TO IMPROVE SURVIVAL  
FOLLOWING RESECTION OF COLORECTAL CANCER **DR. R. AUER**

9:25 – 9:30 APPROVED/ACTIVE TRIALS FOR DISCUSSION

**CO.21:** A PHASE III STUDY OF THE IMPACT OF A PHYSICAL ACTIVITY PROGRAM ON  
DISEASE-FREE SURVIVAL IN PATIENTS WITH EARLY STAGE COLON CANCER: A  
RANDOMIZED CONTROLLED TRIAL (CHALLENGE) **DR. K. COURNEYA/DR. C. BOOTH**

9:30 – 9:55 GUEST PRESENTATION

**FOCUS4:** MOLECULAR SELECTION OF THERAPY IN METASTATIC COLORECTAL CANCER:  
A MOLECULARLY STRATIFIED RANDOMIZED CONTROLLED TRIAL PROGRAMME  
**PROF. T. MAUGHAN**

9:55 CLOSING REMARKS **DR. D. JONKER / DR. S. GILL**